Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Upcoming inexpensive assays for the detection of SARS-CoV-2 RNA in less than one hour at points of care or at home should help suppress the COVID-19 pandemic.
In less than a decade, the genome-editing technology now recognized by the Nobel Prize in Chemistry has impacted the biological and biomedical sciences widely. What’s next for CRISPR in biomedicine?
Two recent high-profile retractions of COVID-19 papers exemplify that trust cannot be taken for granted. To strengthen it, scientific review will have to become more transparent.
Repurposed drugs, inhibitors of inflammatory cytokines, neutralizing monoclonal antibodies and sera from convalescent patients will help ease the burden of COVID-19 on healthcare systems.
Further COVID-19 outbreaks are unavoidable. To detect and suppress them, governments ought to implement a range of public health measures aided by technology.
The world needs mass at-home serological testing for antibodies elicited by SARS-CoV-2, and rapid and frequent point-of-care testing for the presence of the virus’ RNA in selected populations.
Progress in fluorescence-guided systems and contrast agents for real-time intraoperative assistance during tumour-resection operations should benefit patient outcomes.
The integration and miniaturization of components in electronic and photonic devices for interfacing with neural tissue allow for ever more precise neural recording and stimulation.
